NCT00301275|Completed
Loading search results
Sponsor study identifier
observational
N/A
1 country
1
Study Start
June 2002
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
December 2005
Date type not reportedThis date has not been verified as actual or estimated.
Multiple myeloma is a disorder in which malignant plasma cells accumulate in the bone marrow. These plasma cells produce an abnormal protein called paraprotein / M spike in the serum which can be serially monitored to assess the response of tumour on therapy. The paraprotein has a heavy chain which can be either IgG, IgA, IgM or IgD and a light chain which can be either kappa or lambda. At present, these can be assessed by serum and urine electrophoresis (SPE and UPE). These techniques are relatively insensitive and poorly quantitative compared with other immunoassays for tumour markers. The potential of serum free light chain (flc) measurement as a marker for myeloma has been recognised for some time. However, development of such assays has proved elusive, primarily due to the difficulty in developing assays that are both convenient to use and have the required specificity to measure flc in serum. Recently , the assay has been standardised and is in use. Its likely that the assessment of flc might be a sensitive marker of documenting complete remission in patients with myeloma. The aim of this study is to study the flc in patients with myeloma in complete remission (CR) to see if patients have CR documented by standard criteria- are the free light chains still positive and if so are they better markers of remission. The samples will be collected and tested in batches of 60 each.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2005
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 2002
Date type not reportedThis date has not been verified as actual or estimated.
December 2005
Date type not reportedThis date has not been verified as actual or estimated.
March 8, 2006
Actual (reported)March 10, 2006
Actual (reported)Contact the study team to confirm eligibility.
Royal Marsden NHS trust
Sutton, Surrey, SM2 5PT, United Kingdom
Ray Powles, FRCP, FRCpath
Royal Marsden NHS Foundation Trust
First Submitted
March 8, 2006
First Posted
March 10, 2006
Study Start
June 2002
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
December 2005
Date type not reportedThis date has not been verified as actual or estimated.
Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple Myeloma
Last Updated
March 10, 2006
Record last verified: 2006-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: